We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+21%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
+$311M
Cap. Flow
-$51.2M
Cap. Flow %
-1.8%
Top 10 Hldgs %
74.16%
Holding
31
New
1
Increased
10
Reduced
3
Closed
2
Avg Time Held
8.3 quarters
Top 10 Avg Time Held
9.1 quarters
Top 20 Avg Time Held
8.5 quarters

Top Buys

Rank Stock Value
1
MGNX icon
MacroGenics
MGNX
+$27.8M
2
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$26.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$12.5M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$120M
2
TSRO
TESARO, Inc.
TSRO
+$16.8M
3
CELG
Celgene Corp
CELG
+$16.2M
4
PBYI icon
Puma Biotechnology
PBYI
+$9.61M
5
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.88M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INCY icon
1
Incyte
INCY
$22.9B
$366M 12.86%
3,879,822
+39,416
+1% +$3.32M
2013 Q2
13 quarters
CELG
2
DELISTED
Celgene Corp
CELG
$362M 12.71%
3,459,298
-150,000
-4% -$16.2M
2013 Q2
13 quarters
IONS icon
3
Ionis Pharmaceuticals
IONS
$7.41B
$262M 9.23%
7,163,172
+58,334
+0.8% +$1.83M
2013 Q2
13 quarters
RDUS icon
4
DELISTED
Radius Health, Inc.
RDUS
$236M 8.29%
4,360,399
– –
2014 Q2
9 quarters
GILD icon
5
Gilead Sciences
GILD
$187B
$220M 7.72%
2,774,596
– –
2013 Q2
13 quarters
NBIX icon
6
Neurocrine Biosciences
NBIX
$14.4B
$158M 5.56%
3,121,552
– –
2013 Q3
12 quarters
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$145M 5.08%
1,179,428
– –
2013 Q2
13 quarters
AGIO icon
8
Agios Pharmaceuticals
AGIO
$1.87B
$140M 4.92%
2,649,528
+286,207
+12% +$12.5M
2014 Q2
9 quarters
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$130B
$123M 4.34%
1,415,445
– –
2013 Q2
13 quarters
REGN icon
10
Regeneron Pharmaceuticals
REGN
$79B
$98.5M 3.46%
245,000
+40,000
+20% +$16M
2013 Q3
12 quarters
TSRO
11
DELISTED
TESARO, Inc.
TSRO
$97.7M 3.43%
974,582
-180,000
-16% -$16.8M
2013 Q3
12 quarters
HALO icon
12
Halozyme
HALO
$12.6B
$89.1M 3.13%
7,379,832
– –
2013 Q2
13 quarters
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$30.7B
$80.7M 2.84%
1,191,338
– –
2013 Q2
13 quarters
ALDR
14
DELISTED
Alder Biopharmaceuticals
ALDR
$55.2M 1.94%
1,685,150
– –
2015 Q2
5 quarters
CEMP
15
DELISTED
Cempra, Inc.
CEMP
$49.4M 1.74%
2,041,900
– –
2014 Q4
7 quarters
SAGE icon
16
DELISTED
Sage Therapeutics
SAGE
$47.1M 1.66%
1,022,439
+171,800
+20% +$6.99M
2015 Q4
3 quarters
KITE
17
DELISTED
Kite Pharma, Inc.
KITE
$44.7M 1.57%
800,000
+50,000
+7% +$2.79M
2015 Q2
5 quarters
MGNX icon
18
MacroGenics
MGNX
$236M
$43.5M 1.53%
1,455,000
+935,000
+180% +$27.8M
2016 Q2
1 quarter
JUNO
19
DELISTED
Juno Therapeutics, Inc.
JUNO
$42.2M 1.48%
1,405,000
+100,000
+8% +$3.11M
2015 Q2
5 quarters
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$42.1M 1.48%
255,719
– –
2015 Q1
6 quarters
PRTA icon
21
Prothena Corp
PRTA
$441M
$21M 0.74%
350,000
– –
2015 Q3
4 quarters
ITCI icon
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$20.6M 0.72%
1,350,000
+650,000
+93% +$26.3M
2016 Q2
1 quarter
ESPR icon
23
DELISTED
Esperion Therapeutics
ESPR
$18.1M 0.64%
1,308,542
+300,000
+30% +$3.4M
2015 Q3
4 quarters
NVAX icon
24
Novavax
NVAX
$2.1B
$17.3M 0.61%
416,500
– –
2014 Q3
8 quarters
PTCT icon
25
PTC Therapeutics
PTCT
$5.34B
$16.6M 0.58%
1,182,912
– –
2014 Q4
7 quarters
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q3 2016 Portfolio in Review

As of Q3 2016, BB Biotech held 31 positions worth $2.84B, up 12% from $2.53B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

BB Biotech's Q3 2016 filing shows 1 new, 10 increased, 3 reduced and 2 closed positions. Its largest new stake was AveXis, Inc. Common Stock: 352,800 shares worth $14.5M. The largest sale was MEDIVATION, INC., an estimated $120M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • BB Biotech's largest Q3 2016 buy was AveXis, Inc. Common Stock: 352,800 shares worth $14.5M.
  • BB Biotech added most to MacroGenics in Q3 2016, an estimated $27.8M increase.
  • BB Biotech's biggest Q3 2016 reduction was TESARO, Inc., cutting an estimated $16.8M.
  • BB Biotech fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $120M.
  • BB Biotech's ten largest holdings make up 74% of its $2.84B portfolio in Q3 2016.
  • BB Biotech opened 1 new position and closed 2 in Q3 2016.
  • BB Biotech's portfolio value rose 12% quarter-over-quarter to $2.84B.

Based on BB Biotech's 13F filing for Q3 2016, filed 10 Nov 2016.